Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-1002 in Limb Spasticity
NCT05311215Phase 2Active, not recruiting
- Sponsor
- Saol Therapeutics
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Muscle spasm comparing SL-1002 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 26 weeks and Pharmacokinetics. Started Apr 2022; status: active, not recruiting.
02
Drugs
SL-1002
03
Conditions
Muscle spasm
Beyond the preview
Go deeper on NCT05311215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311215.